Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala. In this segment, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, provides a corporate update highlighting the Company’s progress in 2025, key ...